Firebird stent for the treatment of patients with coronary heart disease： short-term clinical outcome

Objective The sirolimus-eluting stent （SES） has dramatically reduced the rate ofrestenosis in comparison to that with the baremetal stent （BMS）.This study aimed to evaluate the short-term efficacy and safety of Firebird stent implantation for patients with coronary heart disease （CHD）. Methods From Apri12006 through July 2007, 155 patients （mean age 58.93±10.27 years ） with CHD were implanted with Firebird stent or Cypher select stent at Daxing Hospital. Patients were followed up for one year. All-cause mortality, major adverse cardiac events （MACE, including cardiac death, myocardial infarction, recurrence of angina pectoris, heart failure, revascularization, and adverse arrhythmia） and stent thrombosis were compared between the 2 groups. Results Of the 155 consecutive patients, 147 patients were revascularized completely. Of these patients, 48 （with 59 lesions） were treated with Firebird stent, 59 patients （with 75 lesions） with Cypher select stent. The demographic characteristics were similar in the 2 groups. All the angiographic and procedural results were not significantly different between the 2 groups. All-cause mortality, myocardial infarction, recurrence of angina pectoris, MACE and stent thrombosis were almost identical between the 2 groups before discharge, at 6 months and at one year .Conclusion The short-term efficacy and safety of Firebird stent are similar to that of the cypher select stent for the treatment of patients with CHD （J Geriatr Cardlo12009; 6：157-161）.